Lexaria Bioscience Corp. (NASDAQ: LEXX) Maintains Late 2022/Early 2023 for Full IND Application for DehydraTECH-CBD
- Lexaria, through its patented DehydraTECH(TM) technology, is improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, thereby achieving an improved speed of onset, and brain absorption of APIs
- Hypertension currently affects nearly 50% of all American adults, with the American Heart Association describing it as a “silent killer”, and is now being studied for its effects during pregnancy
- The company has received positive feedback for its pre-Investigational New Drug meeting from the FDA and has reported that it remains on track to file its full IND application by late 2022/early 2023
- It looks to capitalize on the growth of the antihypertension market, which is set to hit $40 billion by 2031, up from $30.2 billion in 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been on an aggressive push to perfect its potential hypertension treatment, building on its patented DehydraTECH(TM) technology. Through improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, Lexaria can achieve an improved speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”), which is integral to the overall treatment of conditions including but not limited to hypertension.
The American Heart Association (“AHA”) has described hypertension or high blood pressure as a “silent killer,” with nearly 50% of American adults having the condition (https://nnw.fm/VBxuV ). In addition, hypertension during pregnancy comes with severe short-term risks for both mothers and their offspring, although treating the condition among these individuals is still being studied.
A recent Chronic Hypertension And Pregnancy (“CHAP”) study by Tita and colleagues sought to offer more insights into hypertension treatment during pregnancy. With over 2400 participants involved, the group noted that supporting treatment of mild chronic hypertension in pregnancy improved pregnancy outcomes. According to the study’s results, this was primarily due to a reduction in preeclampsia with severe features in medically indicated preterm birth (https://nnw.fm/A7PN2 ).
Typically, the risks associated with hypertension in pregnancy include stroke, pulmonary oedema, acute kidney injury, preeclampsia and eclampsia, placental abruption, or even death. To the offspring, the effects can include preterm birth, birth at small-for-gestational age, or even perinatal death (https://nnw.fm/GmBJy). With such risks, there is a need for effective hypertension treatments during pregnancy. Lexaria is looking to meet that demand.
Through its DehydraTECH technology, Lexaria is looking to meet the serious unmet need in the antihypertension medication market in general and during pregnancy. It aims to achieve this by directly pushing for its products and technology and licensing it for delivering fat-soluble active molecules and drugs to strategic partners worldwide.
Lexaria is also looking to capitalize on the growth of the antihypertension drugs market, which is set to hit $40 billion by 2031, up from $30.2 billion in 2021 (https://nnw.fm/BSTYE ). It also hopes to carve out a significant market share globally and in the United States.
Lexaria’s management is optimistic about the company’s current trajectory. It is confident that with time, its DehydraTECH-CBD for the treatment of hypertension will receive approval from the United States Food and Drug Administration (“FDA”).
The company has so far received positive feedback from its pre-Investigational New Drug meeting (“IND”). John Docherty, Lexaria’s President, has even expressed the company’s delight, citing how helpful this feedback will be in compiling and filing its IND application. As a result, Lexaria remains on track to file its full IND application with the FDA by late 2022/early 2023, as previously announced (https://nnw.fm/VcKpg ).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria, through its patented DehydraTECH(TM) technology, is improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, thereby achieving an improved speed of onset, and brain absorption of APIs
- Hypertension currently affects nearly 50% of all American adults, with the American Heart Association describing it as a “silent killer”, and is now being studied for its effects during pregnancy
- The company has received positive feedback for its pre-Investigational New Drug meeting from the FDA and has reported that it remains on track to file its full IND application by late 2022/early 2023
- It looks to capitalize on the growth of the antihypertension market, which is set to hit $40 billion by 2031, up from $30.2 billion in 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been on an aggressive push to perfect its potential hypertension treatment, building on its patented DehydraTECH(TM) technology. Through improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, Lexaria can achieve an improved speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”), which is integral to the overall treatment of conditions including but not limited to hypertension.
The American Heart Association (“AHA”) has described hypertension or high blood pressure as a “silent killer,” with nearly 50% of American adults having the condition (https://nnw.fm/VBxuV ). In addition, hypertension during pregnancy comes with severe short-term risks for both mothers and their offspring, although treating the condition among these individuals is still being studied.
A recent Chronic Hypertension And Pregnancy (“CHAP”) study by Tita and colleagues sought to offer more insights into hypertension treatment during pregnancy. With over 2400 participants involved, the group noted that supporting treatment of mild chronic hypertension in pregnancy improved pregnancy outcomes. According to the study’s results, this was primarily due to a reduction in preeclampsia with severe features in medically indicated preterm birth (https://nnw.fm/A7PN2 ).
Typically, the risks associated with hypertension in pregnancy include stroke, pulmonary oedema, acute kidney injury, preeclampsia and eclampsia, placental abruption, or even death. To the offspring, the effects can include preterm birth, birth at small-for-gestational age, or even perinatal death (https://nnw.fm/GmBJy). With such risks, there is a need for effective hypertension treatments during pregnancy. Lexaria is looking to meet that demand.
Through its DehydraTECH technology, Lexaria is looking to meet the serious unmet need in the antihypertension medication market in general and during pregnancy. It aims to achieve this by directly pushing for its products and technology and licensing it for delivering fat-soluble active molecules and drugs to strategic partners worldwide.
Lexaria is also looking to capitalize on the growth of the antihypertension drugs market, which is set to hit $40 billion by 2031, up from $30.2 billion in 2021 (https://nnw.fm/BSTYE ). It also hopes to carve out a significant market share globally and in the United States.
Lexaria’s management is optimistic about the company’s current trajectory. It is confident that with time, its DehydraTECH-CBD for the treatment of hypertension will receive approval from the United States Food and Drug Administration (“FDA”).
The company has so far received positive feedback from its pre-Investigational New Drug meeting (“IND”). John Docherty, Lexaria’s President, has even expressed the company’s delight, citing how helpful this feedback will be in compiling and filing its IND application. As a result, Lexaria remains on track to file its full IND application with the FDA by late 2022/early 2023, as previously announced (https://nnw.fm/VcKpg ).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
